Body surface area and epirubicin pharmacokinetics
1998

Epirubicin Dosing and Body Surface Area

Sample size: 32 publication Evidence: moderate

Author Information

Author(s): NA Dobbs, CJ Twelves

Primary Institution: ICRF Clinical Oncology Unit, Guy's Hospital, London

Hypothesis

Does adjusting epirubicin doses for body surface area affect pharmacokinetics and pharmacodynamics?

Conclusion

Adjusting epirubicin doses based on body surface area does not reduce variability in drug clearance or myelosuppression.

Supporting Evidence

  • Unadjusted plasma clearance did not correlate with body surface area.
  • There was no significant difference in variability between adjusted and unadjusted clearance.
  • Neutropenia patterns were similar regardless of dose adjustment for surface area.

Takeaway

Doctors usually change cancer drug doses based on how big a person is, but this study found that it doesn't really help with how the drug works or its side effects.

Methodology

The study evaluated epirubicin pharmacokinetics in 32 women with advanced breast cancer, measuring drug levels and effects without prior anthracycline treatment.

Potential Biases

Potential bias in treatment doses due to patient age and fitness levels.

Limitations

The study had a relatively narrow range of surface areas among participants.

Participant Demographics

All participants were women with advanced breast cancer, aged 35-75 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication